Results for trastusumaab translation from Estonian to English

trastusumaab
trastuzumab

herceptin trastusumaab
herceptin trastuzumab

herceptini toimeaine trastusumaab on monoklonaalne antikeha.
the active substance in herceptin, trastuzumab, is a monoclonal antibody.

trastusumaab peatab ka her2 vähirakkude kasvu stimuleeriva toime.
trastuzumab also stops her2 from stimulating the growth of the cancer cells.

trastusumaab peatab her2 signaalid, mis panevad vähirakud kasvama.
trastuzumab also stops her2 producing signals that cause the tumour cells to grow.

her2-ga seondumisel aktiveerib trastusumaab teatud immuunrakke hävitama kasvajarakke.
by attaching to her2, trastuzumab activates cells of the immune system, which then kill the tumour cells.

trastusumaab on kavandatud seonduma her2-ga, mis on üleekspresseeritud ligikaudu neljandiku rinnavähkide ja viiendiku maovähkide rakkudes.
trastuzumab has been designed to attach to her2, which is overexpressed in about a quarter of breast cancers and a fifth of gastric cancers.

perjetat võrreldi platseeboga (näiv ravim) manustamisel koos teiste vähiravimitega (trastusumaab ja dotsetakseel).
the effects of perjeta were compared with placebo (a dummy treatment) when given together with other cancer medicines (trastuzumab and docetaxel).

trastusumaab on monoklonaalne antikeha (teatud valk), mis tunneb ära valgu her2, mida leidub suures koguses teatud vähirakkude pinnal, ja seondub sellega.
trastuzumab, a monoclonal antibody (a type of protein) that has been designed to recognise and attach to the protein her2, which is found in large quantities on the surface of some cancer cells.

ravimit võib kasutada ka koos teiste vähiravimitega (doksorubitsiin, tsüklofosfamiid, trastusumaab või kapetsitabiin) patsientidel, kellel ei ole vähki veel ravitud, või pärast muude raviskeemide ebaõnnestumist, olenevalt ravitava rinnavähi vormist ja staadiumist; • mitteväikerakk- kopsuvähk.
it can also be used with other anticancer medicines (doxorubicin, cyclophosphamide, trastuzumab or capecitabine) in patients who have not yet received any treatment for their cancer or after other treatments have failed, depending on the type and stage of the breast cancer being treated. • non-small cell lung cancer.